サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566974

細胞毒性薬市場：薬タイプ別、用途別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2024～2033年

Cytotoxic Drug Market By Drug Type , By Application By Route of Administration By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 245 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
細胞毒性薬市場：薬タイプ別、用途別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 245 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞毒性薬市場は2023年に158億米ドルと評価され、2024～2033年にかけてCAGR 2.1%で成長し、2033年には195億米ドルに達すると予測されています。

細胞毒性薬は、DNAに直接作用したり、タンパク質の生合成を阻害したりすることで、がん細胞の増殖を抑制する化学療法剤です。しかし、骨髄、消化管、毛包など頻繁に分裂する健康な細胞にも作用するため、その使用にはしばしば重大な副作用が伴う。このような課題にもかかわらず、細胞毒性薬は様々ながんの治療において依然として不可欠であり、生存率の向上と疾病管理の改善に貢献しています。

世界の細胞毒性薬市場の成長は、がんの憂慮すべき有病率の増加が主要要因です。世界保健機関（WHO）によると、がんは死亡原因の第1位であり、2020年には約1,000万人が死亡すると予測されています。さらに、高齢者人口の急増も世界市場の成長に大きく寄与しています。これは、高齢者ががんに罹患しやすいという事実が、がん治療に対する需要の高まりにつながっているためです。さらに、がんの早期発見と治療に対する意識の高まりが、市場の主要な推進力となっています。米国がん協会は、早期診断されたがん患者の5年生存率が90％であるのに対し、後期診断された患者の5年生存率は20％であることを強調しており、早期発見とそれに伴う治療における細胞毒性薬の使用の重要性を強調しています。治療効果を向上させ副作用を最小限に抑えるため、個々の患者の遺伝子プロファイルに合わせた標的細胞毒性療法の開発が重視されるようになったことが、市場の成長をさらに後押ししています。さらに、経口細胞毒性薬は、その利便性と投与の容易さにより高い支持を得ており、患者のコンプライアンスと生活の質の向上を可能にするため、市場の成長を増強しています。しかし、吐き気、脱毛、骨髄抑制など、細胞毒性薬に関連する副作用がその使用を制限しており、これが世界市場の成長を妨げています。加えて、標的療法、免疫療法、その他の革新的ながん治療など、より効果的な治療法に対する意識の高まりは、従来の細胞毒性薬の需要を減少させる可能性があり、これが市場の主要な阻害要因となっています。これとは逆に、細胞毒性薬の有効性と安全性を高めるためのドラッグ製剤やドラッグデリバリー・システムの革新は、予測期間中の世界市場の成長に有利な機会を提供すると期待されています。例えば、最近の研究では、リポソーム型ドキソルビシンなどの細胞毒性薬の新しい製剤が副作用を軽減し、患者の転帰を改善できることが示されています。臨床試験では、これらの高度な製剤が腫瘍部位へのドラッグデリバリーを30～40％強化できることが実証されています。

世界の細胞毒性薬市場は、薬タイプ、用途、投与経路、流通チャンネル、地域に区分されます。薬タイプでは、アルキル化剤、抗腫瘍抗生物質、代謝拮抗剤、植物アルカロイド、その他に分類されます。用途別では、乳がん、前立腺がん、肺がん、膵臓がん、その他に分類されます。投与経路別では、経口剤と非経口剤に二分されます。流通チャンネルでは、病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダーに細分化されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

薬タイプ別では、2033年に代謝拮抗薬セグメントが市場を独占すると予測されます。

用途別では、乳がんが予測期間中に主要セグメントとして浮上すると予測されます。

投与経路別では、経口剤が今後数年間で最も高い成長を示すと予測されます。

流通チャンネル別では、病院薬局セグメントが近い将来世界細胞毒性薬市場をリードする可能性が高いです。

地域別では、北米が2023年の細胞毒性薬市場の主要株主であり、予測期間を通じてその優位性を維持すると予想されます。

本レポートのカスタマイズが可能です（別途費用とスケジュールが必要です。）

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 細胞毒性薬市場：薬タイプ別

  • 市場概要
  • アルキル化剤
  • 抗腫瘍抗生物質
  • 代謝拮抗薬
  • 植物アルカロイド
  • その他

第5章 細胞毒性薬市場：用途別

  • 市場概要
  • 乳がん
  • 前立腺がん
  • 肺がん
  • 膵臓がん
  • その他

第6章 細胞毒性薬市場：投与経路別

  • 市場概要
  • 経口剤
  • 非経口

第7章 臨床毒性薬市場：流通チャネル別

  • 市場概要
  • 病院薬局
  • ドラッグストアと小売薬局
  • オンラインプロバイダー

第8章 細胞毒性薬市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の細胞毒性薬市場
    • カナダの細胞毒性薬市場
    • メキシコ細胞毒性薬市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの細胞毒性薬市場
    • フランスの細胞毒性薬市場
    • 英国の細胞毒性薬市場
    • イタリアの細胞毒性薬市場
    • スペインの細胞毒性薬市場
    • その他の欧州の細胞毒性薬市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の細胞毒性薬市場
    • 中国の細胞毒性薬市場
    • インドの細胞毒性薬市場
    • オーストラリアの細胞毒性薬市場
    • 韓国の細胞毒性薬市場
    • その他のアジア太平洋の細胞毒性薬市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの細胞毒性薬市場
    • サウジアラビアの細胞毒性薬市場
    • 南アフリカの細胞毒性薬市場
    • その他のラテンアメリカ・中東・アフリカの細胞毒性薬市場

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第10章 企業プロファイル

  • Baxter
  • Cipla Ltd
  • Eli Lilly And Company
  • Fresenius Kabi AG
  • Johnson And Johnson
  • Novartis AG
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
目次
Product Code: A324399

The cytotoxic drug market was valued at $15.8 billion in 2023, and is projected to reach $19.5 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.

Cytotoxic drugs are chemotherapeutic agents that inhibit the growth of cancer cells by acting directly on the DNA or interfering with the biosynthesis of proteins. However, because they also affect healthy cells that divide frequently, such as those in the bone marrow, digestive tract, and hair follicles, their use is often accompanied by significant side effects. Despite these challenges, cytotoxic drugs remain essential in the treatment of various cancers, contributing to improved survival rates and better management of the disease.

The growth of the global cytotoxic drug market is majorly driven by alarming increase prevalence of cancer. According to the World Health Organization, cancer is the leading cause of death, and accounted for approximately 10 million deaths in 2020, thus fueling the demand for effective chemotherapy treatments, including cytotoxic drugs. Moreover, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that aged individuals are highly susceptible to cancer, leading to higher demand for cancer treatments. Furthermore, rise in awareness about early detection and treatment of cancer acts as the key driving force of the market. The American Cancer Society highlights that the five-year survival rate for cancer patients diagnosed at an early stage is 90%, compared to 20% for those diagnosed at a later stage, thereby highlighting the importance of early detection and the consequent use of cytotoxic drugs in treatment. Rise in emphasis on developing targeted cytotoxic therapies tailored to individual patients' genetic profiles to improve treatment efficacy and minimize side effects is further propelling the market growth. In addition, oral cytotoxic drugs are gaining high traction due to their convenience and ease of administration, allowing for better patient compliance and quality of life, thus augmenting the market growth. However, adverse effects associated with cytotoxic drugs, such as nausea, hair loss, and bone marrow suppression, limit their use, which hampers the growth of the global market. In addition, rise in awareness about more effective therapies such as targeted therapies, immunotherapies, and other innovative cancer treatments potentially reduce the demand for traditional cytotoxic drugs, which acts as the key deterrent factor of the market. On the contrary, innovations in drug formulation and delivery systems to enhance the efficacy and safety of cytotoxic drugs are expected to offer lucrative opportunities for the growth of the global market during the forecast period. For instance, recent studies have shown that new formulations of cytotoxic drugs, such as liposomal doxorubicin, can reduce side effects and improve patient outcomes. Clinical trials have demonstrated that these advanced formulations can enhance drug delivery to tumor sites by 30-40%.

The global cytotoxic drug market is segmented into drug type, application, route of administration, distribution channel, and region. On the basis of the drug type, the market is segregated into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. As per application, it is classified into breast cancer, prostate cancer, lung cancer, pancreatic cancer, and others. By route of administration, it is bifurcated into oral and parenteral. According to distribution channel, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug type, the antimetabolites segment is expected to dominate the market by 2033.

On the basis of application, breast cancer is anticipated to emerge as a leading segment during the forecast period.

Depending on route of administration, the oral segment is projected to exhibit the highest growth in the coming years.

As per distribution channel, the hospital pharmacies segment is likely to lead the lobal cytotoxic drug market in the near future.

Region wise, North America was the major shareholder in the cytotoxic drug market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global cytotoxic drug market include Baxter, Cipla Ltd, Eli Lilly and Company, Fresenius Kabi AG, Johnson & Johnson, Novartis AG, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Alkylating Agents
  • Antitumor Antibiotics
  • Antimetabolites
  • Plant Alkaloids
  • Others

By Application

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others

By Route Of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Baxter
    • Cipla Ltd
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Johnson & Johnson
    • Novartis AG
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Alkylating Agents
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Antitumor Antibiotics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Antimetabolites
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Plant Alkaloids
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Prostate Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Lung Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Pancreatic Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Route of Administration
  • 6.2. Oral
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Parenteral
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Drug Type
    • 8.2.3. Market Size and Forecast, By Application
    • 8.2.4. Market Size and Forecast, By Route of Administration
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Cytotoxic Drug Market
      • 8.2.7.1. Market Size and Forecast, By Drug Type
      • 8.2.7.2. Market Size and Forecast, By Application
      • 8.2.7.3. Market Size and Forecast, By Route of Administration
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Cytotoxic Drug Market
      • 8.2.8.1. Market Size and Forecast, By Drug Type
      • 8.2.8.2. Market Size and Forecast, By Application
      • 8.2.8.3. Market Size and Forecast, By Route of Administration
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Cytotoxic Drug Market
      • 8.2.9.1. Market Size and Forecast, By Drug Type
      • 8.2.9.2. Market Size and Forecast, By Application
      • 8.2.9.3. Market Size and Forecast, By Route of Administration
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Drug Type
    • 8.3.3. Market Size and Forecast, By Application
    • 8.3.4. Market Size and Forecast, By Route of Administration
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Cytotoxic Drug Market
      • 8.3.7.1. Market Size and Forecast, By Drug Type
      • 8.3.7.2. Market Size and Forecast, By Application
      • 8.3.7.3. Market Size and Forecast, By Route of Administration
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Cytotoxic Drug Market
      • 8.3.8.1. Market Size and Forecast, By Drug Type
      • 8.3.8.2. Market Size and Forecast, By Application
      • 8.3.8.3. Market Size and Forecast, By Route of Administration
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Cytotoxic Drug Market
      • 8.3.9.1. Market Size and Forecast, By Drug Type
      • 8.3.9.2. Market Size and Forecast, By Application
      • 8.3.9.3. Market Size and Forecast, By Route of Administration
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Cytotoxic Drug Market
      • 8.3.10.1. Market Size and Forecast, By Drug Type
      • 8.3.10.2. Market Size and Forecast, By Application
      • 8.3.10.3. Market Size and Forecast, By Route of Administration
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Cytotoxic Drug Market
      • 8.3.11.1. Market Size and Forecast, By Drug Type
      • 8.3.11.2. Market Size and Forecast, By Application
      • 8.3.11.3. Market Size and Forecast, By Route of Administration
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Cytotoxic Drug Market
      • 8.3.12.1. Market Size and Forecast, By Drug Type
      • 8.3.12.2. Market Size and Forecast, By Application
      • 8.3.12.3. Market Size and Forecast, By Route of Administration
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Drug Type
    • 8.4.3. Market Size and Forecast, By Application
    • 8.4.4. Market Size and Forecast, By Route of Administration
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Cytotoxic Drug Market
      • 8.4.7.1. Market Size and Forecast, By Drug Type
      • 8.4.7.2. Market Size and Forecast, By Application
      • 8.4.7.3. Market Size and Forecast, By Route of Administration
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Cytotoxic Drug Market
      • 8.4.8.1. Market Size and Forecast, By Drug Type
      • 8.4.8.2. Market Size and Forecast, By Application
      • 8.4.8.3. Market Size and Forecast, By Route of Administration
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Cytotoxic Drug Market
      • 8.4.9.1. Market Size and Forecast, By Drug Type
      • 8.4.9.2. Market Size and Forecast, By Application
      • 8.4.9.3. Market Size and Forecast, By Route of Administration
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Cytotoxic Drug Market
      • 8.4.10.1. Market Size and Forecast, By Drug Type
      • 8.4.10.2. Market Size and Forecast, By Application
      • 8.4.10.3. Market Size and Forecast, By Route of Administration
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Cytotoxic Drug Market
      • 8.4.11.1. Market Size and Forecast, By Drug Type
      • 8.4.11.2. Market Size and Forecast, By Application
      • 8.4.11.3. Market Size and Forecast, By Route of Administration
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
      • 8.4.12.1. Market Size and Forecast, By Drug Type
      • 8.4.12.2. Market Size and Forecast, By Application
      • 8.4.12.3. Market Size and Forecast, By Route of Administration
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Drug Type
    • 8.5.3. Market Size and Forecast, By Application
    • 8.5.4. Market Size and Forecast, By Route of Administration
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Cytotoxic Drug Market
      • 8.5.7.1. Market Size and Forecast, By Drug Type
      • 8.5.7.2. Market Size and Forecast, By Application
      • 8.5.7.3. Market Size and Forecast, By Route of Administration
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Cytotoxic Drug Market
      • 8.5.8.1. Market Size and Forecast, By Drug Type
      • 8.5.8.2. Market Size and Forecast, By Application
      • 8.5.8.3. Market Size and Forecast, By Route of Administration
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Cytotoxic Drug Market
      • 8.5.9.1. Market Size and Forecast, By Drug Type
      • 8.5.9.2. Market Size and Forecast, By Application
      • 8.5.9.3. Market Size and Forecast, By Route of Administration
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Cytotoxic Drug Market
      • 8.5.10.1. Market Size and Forecast, By Drug Type
      • 8.5.10.2. Market Size and Forecast, By Application
      • 8.5.10.3. Market Size and Forecast, By Route of Administration
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Baxter
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Cipla Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Eli Lilly And Company
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Fresenius Kabi AG
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Johnson And Johnson
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Viatris Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments